“…In this respect the tumor necrosis factor-α (TNF-α) inhibitors, which rapidly improve clinical signs and symptoms 5,6,7,8 and health-related quality of life (HRQOL) 7,9,10,11 , and inhibit structural damage 7,8,9,12 , have been an important addition to treatment options for patients with RA. Certolizumab pegol (CZP), a PEGylated anti-TNF used either as monotherapy or with methotrexate (MTX), resulted in significant improvement in the signs and symptoms of RA from Week 1 8,13,14 . CZP + MTX also rapidly inhibited the progression of structural damage (as early as Week 16) and were associated with rapid improvements in physical function/HRQOL and pain relief 8,14 .…”